AIM CONCEPT INTEGRATION · 3RD YEAR MBBS · CVS
Ischemic Heart Disease, Angina and Antianginal Drugs
A rapid connection of coronary anatomy, myocardial ischemia, anginal presentation, diagnostic assessment and the actions of major antianginal drugs.
1. THE TOPIC IN ONE CONNECTED FLOW
“`
The myocardium receives blood through the right and left coronary arteries. When myocardial oxygen supply becomes insufficient for its metabolic demand, reversible ischemia produces angina. Prolonged or severe ischemia causes irreversible myocyte death and infarction. Clinical assessment identifies the cause, while antianginal drugs restore the oxygen supply–demand balance.
CORONARY BASIS
Right and left coronary arteries supply oxygenated blood to the myocardium
→
SUPPLY–DEMAND MISMATCH
Fixed narrowing, vasospasm or increased cardiac work reduces effective oxygen delivery
→
MYOCARDIAL ISCHEMIA
Reduced perfusion causes reversible metabolic and functional disturbance without cell death
→
CLINICAL EXPRESSION
Pressure-like chest discomfort may appear during exertion and improve with rest or nitrate
→
ASSESSMENT
History, examination, ECG, biomarkers when indicated and functional or anatomical imaging define the problem
→
THERAPEUTIC ACTION
Nitrates, β-blockers, calcium channel blockers or late sodium-current inhibition improve supply–demand balance
→
POSSIBLE OUTCOME
Persistent severe ischemia may progress from reversible dysfunction to irreversible myocardial infarction
“`
2. KEY CLINICAL CONNECTIONS
“`
Chronic Stable Angina
Fixed coronary narrowing → reduced coronary flow reserve → predictable chest pressure during exertion or emotional stress → relief with rest or sublingual nitrate.
Clinical history → resting ECG may be normal → exercise testing or appropriate coronary imaging helps demonstrate inducible ischemia or coronary disease.
Ischemia versus Infarction
Ischemia → inadequate oxygen supply → reversible cellular dysfunction → anginal pain and possible transient ECG changes.
Prolonged severe ischemia → irreversible myocyte necrosis → infarction → release of cardiac biomarkers and risk of mechanical or electrical complications.
Antianginal Drug Logic
Organic nitrates → nitric oxide-mediated venodilation → reduced preload and myocardial wall stress → lower oxygen demand; headache, flushing and hypotension may occur.
β-blockers or calcium channel blockers → reduced heart rate, contractility or vascular resistance → reduced demand; drug choice depends on the anginal mechanism and patient factors.
Vasospasm and Normal Angiograms
Transient coronary smooth-muscle spasm → sudden reduction in flow → episodic angina, often at rest → improvement with nitrates or calcium channel blockers.
Angina with no major obstructive lesion → possible vasomotor or microvascular dysfunction → ischemic symptoms despite a normal or near-normal coronary angiogram.
Anatomical Link
Coronary arteries run on the heart’s surface and supply its muscular wall → obstruction affects the dependent myocardium. The four valves—tricuspid, pulmonary, mitral and aortic—maintain one-way flow; valve anatomy helps localize heart sounds, while coronary disease primarily impairs myocardial perfusion rather than valve morphology.
“`
3. AIM HIGH-YIELD INTEGRATION REVIEW
“`
⭐ 1. Reduced coronary perfusion or increased myocardial work → oxygen supply–demand mismatch → ischemia and anginal discomfort.
⭐ 2. Ischemia causes reversible dysfunction, whereas infarction represents irreversible myocardial necrosis after prolonged severe ischemia.
⭐ 3. Predictable exertional pain relieved by rest or nitrate → fixed-flow limitation with increased demand → chronic stable angina.
⭐ 4. Nitrates undergo extensive first-pass metabolism, so sublingual administration provides rapid relief → venodilation lowers preload; headache and hypotension are important adverse effects.
5. β-blockade → reduced heart rate and contractility → lower myocardial oxygen demand; this is useful in stable exertional angina but not the preferred mechanism-based therapy for pure vasospastic angina.
6. Calcium channel blockade → arterial and coronary vasodilation, with rate reduction from non-dihydropyridines → relief of stable or vasospastic angina; hypotension, edema, bradycardia or constipation may occur depending on the agent.
7. Late sodium-current inhibition → less intracellular sodium and calcium overload → improved diastolic relaxation and reduced wall tension → angina relief with little direct effect on heart rate or blood pressure.
8. Symptoms may occur despite a normal coronary angiogram → consider transient epicardial spasm or microvascular dysfunction rather than assuming that myocardial ischemia is absent.
AIM EXAM TRAP
Angina is a clinical manifestation of reversible ischemia, not a synonym for myocardial infarction. Infarction requires irreversible myocardial cell death and is supported by cardiac biomarker elevation in the appropriate clinical setting.
“`